Pharmacokinetic crossover trials on GelShield Extended-Release Metformin gut tolerability, topical Diclofenac patch RCTs for targeted joint relief without GI bleeding, and Phase 3 biologic clearance trials in psoriasis and autoimmune disease. Explore 546 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Durable guselkumab efficacy was sustained through 5 years of treatment among patient subpopulations irrespective of baseline disease severity or prior treatment history.
Treatment of patients with HS with ADA resulted in rapid sustained reduction in systemic inflammation, measured by the biomarkers SII, NLR, PLR and MLR, which correlate with CVD risk.
Vunakizumab demonstrated robust clinical response at week 12 and through week 52, with good tolerability in moderate-to-severe plaque psoriasis skin flare-ups skin flare-ups.
Guselkumab is a highly efficacious treatment for plaque psoriasis skin flare-ups skin flare-ups; the study has demonstrated the potential benefit of treatment with guselkumab in reducing systemic inflammation as measured by...
Dupilumab efficacy was similar in patients with COPD and type 2 inflammation, with or without investigator-reported emphysema.
Compared to placebo, both Semaglutide and tirzepatide are associated with increased GI adverse outcomes, with most cases being mild.
Despite QA, protocol deviations persisted during the trial, which were mostly institute-specific.
This study highlighted emotional and social burdens of EoE.
This post-hoc analysis demonstrates the benefit of zavegepant nasal spray over placebo on two patient-centric endpoints: time spent with pain freedom and normal functioning over 48-h post-dose.
Bimekizumab treatment led to rapid improvements in levels of pain and morning stiffness.
Higher pain experienced during labor is associated with cessation of breastfeeding among several other intrapartum interventions and psychological vulnerabilities.
In Japanese patients with RA enrolled in Phase 3 studies for sarilumab, no clear difference in efficacy or safety was observed between patients aged <65 and ≥65 years.
Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis skin flare-ups skin flare-ups.
No important safety finding were observed.
RZB demonstrated good tolerance and efficacy in palmoplantar psoriasis.
A single combined measure of high-sensitivity CRP, LDL cholesterol, and lipoprotein(a) levels among initially healthy U.S.
The median difference between injection and 3 months later was 0.0 blocks/s (interquartile range (IQR) 0.0) on the Box and Block Test, 0/4 (IQR 1) on the Tardieu Scale, 4 degrees (IQR 26) of wrist extension, 0.0 kg (IQR 2) of...
SEC was superior to placebo by efficiently controlling reduced severe itching intensity, clinically normalizing skin lesions, and reversing histopathological abnormalities.
The author describes the results of a study to examine the effect of three treatment regimens on pain associated with endometriosis.
Tegoprazan 50 mg once daily is effective and non-inferior to lansoprazole 30 mg once daily in Chinese patients with DU, showing a promising safety and tolerability profile.
Keverprazan 20 mg twice daily, used as a component of bismuth quadruple therapy, provided effective H.
Adalimumab trough levels above 4.0 mg/L were associated with full symptom relief/low disease activity throughout the first year of adalimumab therapy and can be considered a lower target level for therapeutic drug monitoring...
In this large study of ulcerative colitis patients, we show that few individual species associate strongly with clinical full symptom relief, but multivariate models including microbiome can predict clinical full symptom...
Cr III has shown very promising fast clinical and sonographic results in treating RA patients which were surprisingly superior to baricitinib in most aspects.
Ozanimod is an effective, durable, and well-tolerated oral therapy for AT-naive ulcerative colitis patients.
GLM was effective in autoimmune joint pain (autoimmune joint pain (rheumatoid arthritis)) patients in a subpopulation at high risk of PPF in GO-FORTH study.
Irrespective of the uveitic anatomic subtype among patients treated for ME associated with NIU, a clinical benefit in participants treated with CLS-TA was demonstrated, with a comparable safety profile.
Treatment with baricitinib 4 mg or 2 mg demonstrated efficacy up to 6.5 years with maintained LDA/full symptom relief results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated.
This study highlights the prevalence of GI AE in patients receiving metformin, with a diarrhea predominance, followed by bloating, diarrhea, abdominal pain, constipation, and vomiting.
Conversely, during maintenance up to week 52, increasing the concentration via dose translated to better responses more robustly.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
